Evidence map›Paper›PMID 41749341›Full record

Trial reportTrials2026

panTB-HM: a multi-arm clinical trial of a pan-TB regimen targeting both host and microbe.

D Mudzengi, S Mashatole, Q Xiang, C Adrion, N Glover, T Ngwanto, J Mdluli, S Boniface, M Rassool, B Matome and 30 more

Registry-linked trialAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05686356 (A Novel 4-month Pan-TB Regimen Targeting Both Host and Microbe), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05686356 phase2 / phase3active not recruitingnot on this map

A Novel 4-month Pan-TB Regimen Targeting Both Host and Microbe (panTB-HM)

TypeinterventionalSponsorThe Aurum Institute NPCRan2023 to 2026Enrolled352ConditionsTuberculosisArmsSutezolid, N-acetyl cysteine, Pretomanid, Bedaquiline, Rifafour
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

40 authors.

D MudzengiAurum Institute, Johannesburg, South Africa. dmudzengi@auruminstitute.org.
S MashatoleAurum Institute, Johannesburg, South Africa.
Q XiangAurum Institute, Johannesburg, South Africa.
C AdrionLMU, Munich, Germany.
N GloverAurum Institute, Johannesburg, South Africa.
T NgwantoAurum Institute, Johannesburg, South Africa.
J MdluliAurum Institute, Johannesburg, South Africa.
S BonifaceNIMR Mbeya Medical Research Center, Mbeya, Tanzania.
M RassoolClinical HIV Research Unit, Wits Health Consortium, Johannesburg and Durban, South Africa.
B MatomeClinical HIV Research Unit, Wits Health Consortium, Johannesburg and Durban, South Africa.
L ParamoLMU, Munich, Germany.
E SvenssonRadboud Medical Center, Nijmegen, The Netherlands.
A FasanmiAurum Institute, Johannesburg, South Africa.
S AngeloAurum Institute, Johannesburg, South Africa.
M MoyoAurum Institute, Johannesburg, South Africa.
C MarxAurum Institute, Johannesburg, South Africa.
C KhosaInstituto Nacional de Saúde, Marracuene, Mozambique.
L MokabaAurum Institute, Johannesburg, South Africa.
N MofokengAurum Institute, Johannesburg, South Africa.
J LalashowiNIMR Mbeya Medical Research Center, Mbeya, Tanzania.
C NacySequella, Rockville, USA.
S CharalambousAurum Institute, Johannesburg, South Africa.
E FumaneInstituto Nacional de Saúde, Marracuene, Mozambique.
V MaphossaInstituto Nacional de Saúde, Marracuene, Mozambique.
T BeattieAurum Institute, Johannesburg, South Africa.
W BrumskineAurum Institute, Johannesburg, South Africa.
C VenterTecro Research, Bloemfontein, South Africa.
D MapambaNIMR Mbeya Medical Research Center, Mbeya, Tanzania.
N HeinrichLMU, Munich, Germany.
S RajaramClinical HIV Research Unit, Wits Health Consortium, Johannesburg and Durban, South Africa.
S KooverjeeClinical HIV Research Unit, Wits Health Consortium, Johannesburg and Durban, South Africa.
L BothaTASK Clinical Trials, George, South Africa.
M NellTASK Clinical Trials, George, South Africa.
A EastonTASK Clinical Trials, George, South Africa.
S ForaidaTB Alliance, New York, USA.
Robin Mark WarrenStellenbosch University, Cape Town, South Africa.
Issa SabiNIMR Mbeya Medical Research Center, Mbeya, Tanzania.
N NtinginyaNIMR Mbeya Medical Research Center, Mbeya, Tanzania.
R S WallisAurum Institute, Johannesburg, South Africa. rswallis@gmail.com.
panTB-HM Consortium

Funding

EDCTP RIA2019AMR-2647
6 · The paper itself

Abstract

backgroundNewer oxazolidinones will be required to advance regimens in pan-TB indications. The addition of host-directed agents may help promote the recovery of lung function during TB treatment and prevent post-TB lung disease.

methodsThe panTB-HM trial assesses the capacity of three novel regimens containing the oxazolidinone sutezolid and the antioxidant N-acetylcysteine (NAC) to meet the target criteria proposed by WHO for pan-TB indications (including use without rifamycin susceptibility testing and of 4 months or less duration) in a phase 2C trial. DISCUSSION: This trial is ground-breaking in its objectives and design for a 4-month pan-TB indication (in a non-inferiority comparison to standard treatment) and its evaluation of lung function recovery (in a superiority comparison).

trial registrationClinicalTrials.gov NCT05686356. Registered on 13 Jan 2023.

Indexed as

AcetylcysteineAntioxidantsAntitubercular AgentsLungMycobacterium tuberculosisOxazolidinonesThiazolidinesTuberculosis, PulmonaryDrug Therapy, CombinationHost-Directed TherapyHumansRecovery of FunctionResearch DesignTetrazolesTime FactorsTreatment OutcomeAcetylcysteineAntioxidantsAntitubercular AgentsOxazolidinonestedizolidTetrazolesThiazolidines

Identifiers

PMID41749341
PMCPMC13049951

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.